The members of the Rel/NF-kappa B family of transcription factors form one
of the first lines of defense against infectious diseases and cellular stre
ss. These proteins initiate a highly coordinated response in multiple cell
types that effectively counteracts the threat to the health of the organism
, Conversely, disruption of the regulatory mechanisms that control the spec
ificity and extent of this response, which results in aberrant activation o
f NF-kappa B, can be one of the primary causes of a wide range of human dis
eases. Thus, targeting NF-kappa B might lead to the development of new phar
maceutical reagents that could provide novel treatments for many inflammato
ry diseases and cancer.